Lexaria Bioscience (LEXX) Current Leases (2020 - 2026)
Lexaria Bioscience (LEXX) posted Current Leases of $33035.0 for Q2 2026, up 3.04% sequentially from $32060.0 in Q1 2026, and up 10.59% YoY from $29872.0 in Q2 2025.
Lexaria Bioscience (LEXX) Current Leases (2020 - 2026) Analysis & Trends
Lexaria Bioscience has reported Current Leases for 7 years, with the latest figure at $33035.0 in Q2 2026.
- Quarterly Current Leases rose 10.59% year-over-year to $33035.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $33035.0 (up 10.59% YoY) and the FY2025 annual result came in at $30417.0, up 8.45% from the prior year.
- Current Leases rose to $33035.0 in Q2 2026 per LEXX's latest filing, from $32060.0 in the prior quarter.
- Over five years, Current Leases peaked at $42587.0 in Q3 2022 and troughed at $25554.0 in Q4 2023.
- A 5-year average of $32011.2 and a median of $30144.5 in 2025 frame the typical range for Current Leases.
- The sharpest annual moves came in 2023 and 2024: Current Leases plunged 35.52% in 2023, then advanced 12.75% in 2024.
- Over 5 years, Current Leases stood at $39629.0 in 2022, then slumped by 35.52% to $25554.0 in 2023, then advanced by 12.75% to $28812.0 in 2024, then grew by 7.94% to $31101.0 in 2025, then grew by 6.22% to $33035.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $33035.0, $32060.0, and $31101.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | - |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - | 33,035.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 33,035.00 |
| Feb 28, 2026 | 32,060.00 |
| Nov 30, 2025 | 31,101.00 |
| Aug 31, 2025 | 30,417.00 |
| May 31, 2025 | 29,872.00 |
| Feb 28, 2025 | 29,337.00 |
| Nov 30, 2024 | 28,812.00 |
| Aug 31, 2024 | 28,047.00 |
| May 31, 2024 | 27,260.00 |
| Feb 29, 2024 | 26,399.00 |
| Nov 30, 2023 | 25,554.00 |
| Aug 31, 2023 | 27,794.00 |
| May 31, 2023 | 32,317.00 |
| Feb 28, 2023 | 29,080.00 |
| Nov 30, 2022 | 39,629.00 |
| Aug 31, 2022 | 42,587.00 |
| May 31, 2022 | 41,825.00 |
| Feb 28, 2022 | 41,076.00 |
| Aug 31, 2021 | 39,404.00 |
| May 31, 2021 | 38,485.00 |